EGFR and non-small cell lung carcinoma: 18F-FDG PET/CT has been demonstrated to have a powerful efficacy to predict the EGFR mutation status in patients with NSCLC, not only based on conventional PET/CT parameters (e.g., SUVmax, MTV, and TLG) but also based on radiomics of PET/CT.